Northwest Biotherapeutics (NWBO) 7.37 $NWBO Nor
Post# of 64074
Posted On: 02/28/2015 8:06:13 PM
Northwest Biotherapeutics (NWBO) 7.37 $NWBO
Northwest Bio cleared to begin DCVax-L study in Canada
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:31PM CST
NWBO: 7.37 (-0.09)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.37 (-0.09), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68)
Northwest Biotherapetuics (NWBO) is Undervalued and Has Crossed Above Its SqueezeTrigger Price.
M2 - Thu Feb 05, 4:08AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report today on Northwest Biotherapeutics (NASDAQ: NWBO). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.86 and the projected short squeeze valuation of $10.76 per share.
NWBO: 7.37 (-0.09)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/98lwfp/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. During the 2013-2020 forecast period, the GBM market is expected to grow rapidly from $301m to $623m. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope: - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2020, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Reasons to Purchase: - Understand the different levels of GBM therapies for newly diagnosed and recurrent GBM - Understand the vast scope of the pipeline and determine which molecule types and mechanisms of action are prominent - Observe the trends in clinical trial duration and size by clinical Phase and molecule type, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for GBM therapeutics - Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the GBM therapeutics market For more information visit http://www.researchandmarkets.com/research/98...ioblastoma
NWBO: 7.37 (-0.09), MRK: 58.54 (-0.42)
NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum
PR Newswire - Fri Jan 23, 12:06PM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that CEO Linda Powers will present at the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C.
NWBO: 7.37 (-0.09)
NW Bio To Present At Biotech Showcase Conference
PR Newswire - Thu Jan 08, 1:46PM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda Powers will present at the Biotech Showcase conference in San Francisco.
NWBO: 7.37 (-0.09)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 168.65 (-0.96), NWBO: 7.37 (-0.09), MRK: 58.54 (-0.42), IMUC: 0.57 (-0.02)
Is Northwest Biotherapeutics A Bargain? Yes!
Ryan Pawell - at Seeking Alpha - Sun Jan 04, 11:17PM CST
NWBO: 7.37 (-0.09), CLDX: 25.54 (+0.60)
Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 95.32 (-0.90), NWBO: 7.37 (-0.09), GILD: 103.53 (-0.66), DNDN: 0.13 (-0.02), ICPT: 221.37 (+2.30), JUNO: 46.92 (-0.68), GALE: 1.80 (-0.03), AGIO: 107.28 (-0.48), AEGR: 27.20 (+0.20), ABBV: 60.50 (-0.02), BMY: 60.92 (-0.54), MNKD: 6.52 (-0.30), CELG: 121.53 (-1.82)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 7.37 (-0.09), DNDN: 0.13 (-0.02), RTRX: 14.16 (-0.74), CYTR: 3.23 (-0.10), RPRX: 9.21 (-0.28), GALE: 1.80 (-0.03), AEGR: 27.20 (+0.20)
This Illegal Drug Could Be the Answer to Fighting Brain Cancer
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 14, 10:41AM CST
Source: National Cancer Institute via Wikimedia Commons. There's pretty much nothing scarier than being told you have cancer. Although I've personally never been given this dreaded diagnosis, I was there by my mother's side when she was told in...
NWBO: 7.37 (-0.09)
NW BIO RECAPS 2014 PROGRESS, PROVIDES DCVAX-DIRECT TRIAL UPDATE AT OPPENHEIMER'S 25TH ANNUAL HEALTHCARE CONFERENCE
PR Newswire - Thu Dec 11, 10:59AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that NW Bio's CEO, Linda Powers, recapped the substantial progress made by the Company during 2014 in a presentation at Oppenheimer's 25th Annual Healthcare Conference in New York City.
NWBO: 7.37 (-0.09)
Northwest Biotherapeutics: An Analysis Of What We Know About DCVax Direct
Smith On Stocks - at Seeking Alpha - Mon Dec 01, 5:23AM CST
NWBO: 7.37 (-0.09), KITE: 65.44 (-2.05)
Commit To Buy Northwest Biotherapeutics At $3, Earn 25% Using Options
StockOptionsChannel.com - Wed Nov 26, 10:34AM CST
Investors considering a purchase of Northwest Biotherapeutics Inc stock, but cautious about paying the going market price of $5.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NWBO: 7.37 (-0.09)
Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST
NWBO: 7.37 (-0.09), DNDN: 0.13 (-0.02)
Update: Northwest Bio Benefits From Two Financings, Woodford Makes Encouraging Investment
Trevor Lowenthal - at Seeking Alpha - Fri Nov 21, 7:16AM CST
NWBO: 7.37 (-0.09)
Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
at The Street - Fri Nov 21, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 7.37 (-0.09), CLDX: 25.54 (+0.60), MNKD: 6.52 (-0.30), PBYI: 213.01 (+7.05)
Northwest Biotherapeutics posts 3Q loss
Automated Insights - Thu Nov 20, 5:51PM CST
BETHESDA, Md. (AP) _ Northwest Biotherapeutics Inc. (NWBO) on Thursday reported a loss of $21 million in its third quarter.
NWBO: 7.37 (-0.09)
Northwest Bio cleared to begin DCVax-L study in Canada
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 3:31PM CST
NWBO: 7.37 (-0.09)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.37 (-0.09), KITE: 65.44 (-2.05), JUNO: 46.92 (-0.68)
Northwest Biotherapetuics (NWBO) is Undervalued and Has Crossed Above Its SqueezeTrigger Price.
M2 - Thu Feb 05, 4:08AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report today on Northwest Biotherapeutics (NASDAQ: NWBO). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.86 and the projected short squeeze valuation of $10.76 per share.
NWBO: 7.37 (-0.09)
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
M2 - Fri Jan 23, 9:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/98lwfp/glioblastoma) has announced the addition of the "Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" report to their offering. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck's Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche's Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. During the 2013-2020 forecast period, the GBM market is expected to grow rapidly from $301m to $623m. The market entry of Northwest Biotherapeutics' DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth. Having demonstrated superior OS improvement compared with the standard treatment alone in clinical trials, it is expected to bear high market potential, given that its efficacy is translated into larger Phase III trials. The cancer vaccine Rindopepimut (CDX-110) and targeted therapy Cotara will also enter the GBM market, but will drive growth to a lesser extent. However, unmet needs are likely to remain in the relapsed setting over the forecast period due to the lack of superior OS benefits in the late-stage pipeline. Scope: - A brief introduction to GBM, including the disease pathogenesis, risk factors and diagnosis - In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy - A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target - Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate - Multi-scenario forecast data for the GBM market to 2020, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain - Discussion of the drivers of and barriers to market growth - Discussion of the licensing and co-development deals landscape in GBM Reasons to Purchase: - Understand the different levels of GBM therapies for newly diagnosed and recurrent GBM - Understand the vast scope of the pipeline and determine which molecule types and mechanisms of action are prominent - Observe the trends in clinical trial duration and size by clinical Phase and molecule type, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for GBM therapeutics - Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the GBM therapeutics market For more information visit http://www.researchandmarkets.com/research/98...ioblastoma
NWBO: 7.37 (-0.09), MRK: 58.54 (-0.42)
NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum
PR Newswire - Fri Jan 23, 12:06PM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that CEO Linda Powers will present at the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. NWBO: 7.37 (-0.09)
NW Bio To Present At Biotech Showcase Conference
PR Newswire - Thu Jan 08, 1:46PM CST
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that CEO Linda Powers will present at the Biotech Showcase conference in San Francisco. NWBO: 7.37 (-0.09)
Dendritic Cell Cancer Vaccine Market & Clinical Insight 2015
M2 - Tue Jan 06, 4:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/2xq75j/dendritic_cell) has announced the addition of the "Dendritic Cell Cancer Vaccine Market & Clinical Insight" report to their offering. The high pace of research and development along with initial positive results in experimental studies is expected to create large market for dendritic cell based cancer vaccines. The design of dendritic cell cancer vaccine is likely to improve and much emphasis will be on multiple cancer antigen targeting capabilities of a single molecule. Computer technology is helping oncologists to design and run simulations on these hypothetical vaccines to check their effect on cellular machinery even before going to laboratory and consuming precious resources. This technology could also save lots of time by performing analysis on hundreds of probable vaccine candidates in single experiment. However, the results of such dendritic cell cancer vaccines remain elusive in clinical trials which may be marketed if they produce the significant pharmacological effects in eradicating the cancer. Dendritic Cell Vaccine Market & Clinical Insight Report Highlights: - Dendritic Cell Cancer Vaccine in Clinical Pipeline: 52 - Majority of Dendritic Cell Cancer Vaccine in Phase-II: 13 - Marketed Dendritic Cell Cancer Vaccine: 3 (CreaVax, Provenge & DC-CIK) Key Topics Covered: 1. Introduction to Dendritic Cell Cancer Vaccines 2. Mechanism of Dendritic Cell Cancer Vaccine 3. Dendritic Cell Cancer Vaccine Market Overview 4. Dendritic Cell Cancer Vaccine Market Dynamics 5. Dendritic Cell Cancer Vaccine Future Prospects 6. Dendritic Cell Cancer Vaccine Clinical Insight by Phase, Indication & Company 7. Marketed Dendritic Cell Cancer Vaccine Clinical Insight 8. Suspended & Discontinued Clinical Trials Insight 9. Competitive Landscape - 3M Company - Activartis - Batavia Bioservices - Creagene - Dendreon - Merck - Northwest Biotherapeutics - Glaxo Smith Kline - ImmunoCellular Therapeutics - Tella Incorporation For more information visit http://www.researchandmarkets.com/research/2x...ritic_cell
MMM: 168.65 (-0.96), NWBO: 7.37 (-0.09), MRK: 58.54 (-0.42), IMUC: 0.57 (-0.02)
Is Northwest Biotherapeutics A Bargain? Yes!
Ryan Pawell - at Seeking Alpha - Sun Jan 04, 11:17PM CST
NWBO: 7.37 (-0.09), CLDX: 25.54 (+0.60)
Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 95.32 (-0.90), NWBO: 7.37 (-0.09), GILD: 103.53 (-0.66), DNDN: 0.13 (-0.02), ICPT: 221.37 (+2.30), JUNO: 46.92 (-0.68), GALE: 1.80 (-0.03), AGIO: 107.28 (-0.48), AEGR: 27.20 (+0.20), ABBV: 60.50 (-0.02), BMY: 60.92 (-0.54), MNKD: 6.52 (-0.30), CELG: 121.53 (-1.82)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 7.37 (-0.09), DNDN: 0.13 (-0.02), RTRX: 14.16 (-0.74), CYTR: 3.23 (-0.10), RPRX: 9.21 (-0.28), GALE: 1.80 (-0.03), AEGR: 27.20 (+0.20)
This Illegal Drug Could Be the Answer to Fighting Brain Cancer
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 14, 10:41AM CST
Source: National Cancer Institute via Wikimedia Commons. There's pretty much nothing scarier than being told you have cancer. Although I've personally never been given this dreaded diagnosis, I was there by my mother's side when she was told in...
NWBO: 7.37 (-0.09)
NW BIO RECAPS 2014 PROGRESS, PROVIDES DCVAX-DIRECT TRIAL UPDATE AT OPPENHEIMER'S 25TH ANNUAL HEALTHCARE CONFERENCE
PR Newswire - Thu Dec 11, 10:59AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that NW Bio's CEO, Linda Powers, recapped the substantial progress made by the Company during 2014 in a presentation at Oppenheimer's 25th Annual Healthcare Conference in New York City. NWBO: 7.37 (-0.09)
Northwest Biotherapeutics: An Analysis Of What We Know About DCVax Direct
Smith On Stocks - at Seeking Alpha - Mon Dec 01, 5:23AM CST
NWBO: 7.37 (-0.09), KITE: 65.44 (-2.05)
Commit To Buy Northwest Biotherapeutics At $3, Earn 25% Using Options
StockOptionsChannel.com - Wed Nov 26, 10:34AM CST
Investors considering a purchase of Northwest Biotherapeutics Inc stock, but cautious about paying the going market price of $5.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NWBO: 7.37 (-0.09)
Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST
NWBO: 7.37 (-0.09), DNDN: 0.13 (-0.02)
Update: Northwest Bio Benefits From Two Financings, Woodford Makes Encouraging Investment
Trevor Lowenthal - at Seeking Alpha - Fri Nov 21, 7:16AM CST
NWBO: 7.37 (-0.09)
Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
at The Street - Fri Nov 21, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 7.37 (-0.09), CLDX: 25.54 (+0.60), MNKD: 6.52 (-0.30), PBYI: 213.01 (+7.05)
Northwest Biotherapeutics posts 3Q loss
Automated Insights - Thu Nov 20, 5:51PM CST
BETHESDA, Md. (AP) _ Northwest Biotherapeutics Inc. (NWBO) on Thursday reported a loss of $21 million in its third quarter.
NWBO: 7.37 (-0.09)
(0)
(0)Scroll down for more posts ▼